Alternative NF-kB activation after chemotherapy in ovarian cancer
Official title: Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse
Funded at San Diego State University · NIH-11473227 · Data updated 2026-11-12
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | San Diego State University NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $87,191 |
| NIH project number | 3R01CA260281-05S1 |
| Project ID | NIH-11473227 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are women with ovarian cancer who have received chemotherapy and are at risk of relapse or who have relapsed disease, particularly those with chemoresistant tumors.
✕Less likely to help
Patients whose cancer does not involve TIC-driven relapse or whose tumors do not rely on alternative NF-kB signaling may see limited direct benefit.
What this research studies
Researchers at San Diego State University will explore how chemotherapy changes the tumor environment and activates alternative NF-kB signaling in tumor-initiating cells, which may help the cancer survive and re-grow. They will examine molecular pathways and how these cells resist treatment, with a focus on factors in the surrounding tissue that could trigger relapse. The project aims to identify potential targets to combine with chemotherapy to delay or prevent recurrence and improve long-term remissions for patients. Findings could pave the way for new strategies to keep ovarian cancer from returning after initial therapy.
Why it matters
Potential benefit: If successful, the work could lead to new treatment approaches that reduce relapse and prolong remission for ovarian cancer patients.
How similar studies have gone: Previous research suggests targeting TICs and related signaling pathways can influence chemoresistance, but direct translation to relapse prevention in humans remains to be proven.
Where this research is happening
-
San Diego State University
San Diego, United States Active
Researchers
- Principal investigator: House, Carrie Danielle — San Diego State University
- Study coordinator: House, Carrie Danielle
Related research
Other NIH-funded projects on the same topics.
-
Understanding how chemotherapy-related changes fuel ovarian cancer relapse
Aims to uncover how changes after chemotherapy help ovarian cancer come back and how to block those signals to help patients stay cancer-free.
-
Why ovarian cancer can come back after chemotherapy — the role of NF-kB signaling
Researchers are looking at whether signals called alternative NF-kB, triggered after chemotherapy, help drug-resistant tumor-initiating cells survive and cause ovarian cancer to return in women treated for ovarian cancer.
-
Why ovarian cancer returns after chemotherapy — the role of an alternative NF‑κB signal
This project looks at whether a signaling pathway called alternative NF‑κB helps chemo‑resistant ovarian cancer cells survive and lead to relapse in women treated for ovarian cancer.
-
Understanding how ovarian cancer can come back after chemotherapy
This study is looking into why ovarian cancer sometimes comes back after treatment, especially focusing on certain stubborn cancer cells that survive chemotherapy, and it aims to find new ways to stop this from happening so that patients can have better treatment options.
-
Understanding how ovarian cancer can come back after chemotherapy
This study is looking into why ovarian cancer sometimes comes back after treatment, especially focusing on a tough group of cancer cells that resist chemotherapy, to find new ways to stop the cancer from returning and help patients feel better.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.